×
About 110,580 results

ALLMedicine™ Leukemia Center

Research & Reviews  51,361 results

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytar...
https://doi.org/10.3324/haematol.2020.263392
Haematologica Swaminathan M, Kantarjian HM et. al.

Apr 15th, 2021 - FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation in acute myeloid leukemia (AML) is associated with poor prognosis. We hypothesized that quizartinib, a selective and potent FLT3 inhibitor, with azacitidine (AZA) or low-do...

Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to veneto...
https://doi.org/10.3324/haematol.2020.272609
Haematologica Cojocari D, Smith BN et. al.

Apr 15th, 2021 - Dysregulation of apoptotic machinery is one mechanism by which acute myeloid leukemia (AML) acquires a clonal survival advantage. B-cell lymphoma protein-2 (BCL2) overexpression is a common feature in hematologic malignancies. The selective BCL2 i...

The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/r...
https://doi.org/10.1080/14740338.2021.1913120
Expert Opinion on Drug Safety; Marconi G, Giannini MB et. al.

Apr 15th, 2021 - FLT3 inhibitors are important drugs in the therapy of FLT3 positive acute myeloid leukemia (AML). Midostaurin was registered in combination with chemotherapy to treat newly diagnosed AML. Gilteritinib and quizartinib demonstrate effectiveness in a...

The shape of low-concentration dose-response functions for benzene: implications for hu...
https://doi.org/10.1080/10408444.2020.1860903
Critical Reviews in Toxicology; Cox LA, Ketelslegers HB et. al.

Apr 15th, 2021 - Are dose-response relationships for benzene and health effects such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) supra-linear, with disproportionately high risks at low concentrations, e.g. below 1 ppm? To investigate this hy...

Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine...
https://doi.org/10.1080/16078454.2021.1912949
Hematology (Amsterdam, Netherlands); Tangchitpianvit K, Rattarittamrong E et. al.

Apr 15th, 2021 - The primary objective was to compare the efficacy of intermediate-dose cytarabine (IDAC) and high-dose cytarabine (HiDAC) as consolidation chemotherapy for acute myeloid leukemia (AML) in terms of a one-year-relapse-free survival rate (RFS). The s...

see more →

Guidelines  139 results

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myel...
https://doi.org/10.1016/j.bbmt.2020.09.020
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.

Sep 23rd, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

Ivosidenib Plus Venetoclax With or Without Azacitidine for IDH1-Mutated AML
https://ascopost.com/news/june-2020/ivosidenib-plus-venetoclax-with-or-without-azacitidine-for-idh1-mutated-aml/

May 31st, 2020 - Combination therapy with the isocitrate dehydrogenase 1 (IDH1) inhibitor ivosenidib plus the BCL2 inhibitor venetoclax with or without the chemotherapeutic agent azacitidine showed activity in patients with IDH1-mutated acute myeloid leukemia (AML...

AMG 330 Shows Promise in Treating Relapsed/Refractory AML
https://www.onclive.com/conference-coverage/asco-2020/amg-330-shows-promise-in-treating-relapsedrefractory-aml

May 29th, 2020 - Findings showed that AMG 330 was safe and tolerable in treating patients with relapsed or refractory acute myeloid leukemia (AML), with cytokine release syndrome (CRS) as the most frequent and expected adverse event (AE), according to preliminary ...

Palliative Care Improves Quality of Life in Patients With AML
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200172/full/

May 28th, 2020 - When patients with acute myeloid leukemia (AML) undergo intensive chemotherapy treatment, their quality of life (QoL) and mood are negatively affected. Areej El-Jawahri, MD, of Massachusetts General Hospital, presented the results of a multicenter...

Strict Cytogenetics, MRD Criteria Identifies Pediatric B-ALL Subgroup With Favorable Prognosis
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200195/full/

May 28th, 2020 - Application of a set of stringent clinical and cytogenetic features as well as minimal residual disease (MRD) criteria can identify a subset of low-risk (LR) pediatric patients with standard-risk B-cell acute lymphoblastic leukemia (B-ALL) who can...

see more →

Drugs  381 results see all →

Clinicaltrials.gov  54,825 results

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytar...
https://doi.org/10.3324/haematol.2020.263392
Haematologica Swaminathan M, Kantarjian HM et. al.

Apr 15th, 2021 - FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation in acute myeloid leukemia (AML) is associated with poor prognosis. We hypothesized that quizartinib, a selective and potent FLT3 inhibitor, with azacitidine (AZA) or low-do...

Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to veneto...
https://doi.org/10.3324/haematol.2020.272609
Haematologica Cojocari D, Smith BN et. al.

Apr 15th, 2021 - Dysregulation of apoptotic machinery is one mechanism by which acute myeloid leukemia (AML) acquires a clonal survival advantage. B-cell lymphoma protein-2 (BCL2) overexpression is a common feature in hematologic malignancies. The selective BCL2 i...

The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/r...
https://doi.org/10.1080/14740338.2021.1913120
Expert Opinion on Drug Safety; Marconi G, Giannini MB et. al.

Apr 15th, 2021 - FLT3 inhibitors are important drugs in the therapy of FLT3 positive acute myeloid leukemia (AML). Midostaurin was registered in combination with chemotherapy to treat newly diagnosed AML. Gilteritinib and quizartinib demonstrate effectiveness in a...

The shape of low-concentration dose-response functions for benzene: implications for hu...
https://doi.org/10.1080/10408444.2020.1860903
Critical Reviews in Toxicology; Cox LA, Ketelslegers HB et. al.

Apr 15th, 2021 - Are dose-response relationships for benzene and health effects such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) supra-linear, with disproportionately high risks at low concentrations, e.g. below 1 ppm? To investigate this hy...

Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine...
https://doi.org/10.1080/16078454.2021.1912949
Hematology (Amsterdam, Netherlands); Tangchitpianvit K, Rattarittamrong E et. al.

Apr 15th, 2021 - The primary objective was to compare the efficacy of intermediate-dose cytarabine (IDAC) and high-dose cytarabine (HiDAC) as consolidation chemotherapy for acute myeloid leukemia (AML) in terms of a one-year-relapse-free survival rate (RFS). The s...

see more →

News  3,813 results

Allo-HSCT Plus MAb Can Boost Survival in Patients With r/r B-ALL
https://www.medscape.com/viewarticle/948153

Mar 24th, 2021 - The use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) can improve survival in minimal residual disease (MRD)-negative remission patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) after the start...

New BTK Inhibitor Pirtobrutinib Shows Promise in CLL
https://www.medscape.com/viewarticle/947440

Mar 14th, 2021 - Pirtobrutinib treatment yielded promising outcomes in chronic lymphocytic leukemia (CLL) and other patients with B-cell malignancies who discontinued prior Bruton's tyrosine kinase (BTK)–inhibitor treatment due to resistance or intolerance, accord...

Whole-Genome Sequencing Emerging for Routine Cancer Care
https://www.medscape.com/viewarticle/947261

Mar 10th, 2021 - Almost 20 years after the human genome was first mapped, whole-genome sequencing might finally be ready to enter routine cancer care. Researchers at Washington University in St. Louis, St. Louis, Missouri, are commercializing an automated sequenci...

Blood Cancer Patients, Survivors Hesitate Over COVID-19 Vaccine
https://www.medscape.com/viewarticle/947202

Mar 9th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Nearly one in three patients with blood cancer and survivors say they are unlikely to get a COVID-19 vaccine or unsure about getting it if one wer...

Clear Benefit of Blinatumomab in Kids With Relapsed B-Cell Lymphoma
https://www.medscape.com/viewarticle/946711

Mar 2nd, 2021 - NEW YORK (Reuters Health) - Two randomized trials show a clear benefit of blinatumomab in combination with conventional chemotherapy in children with high-risk relapsed B-cell acute lymphoblastic leukemia (B-ALL), with improved outcomes and a favo...

see more →

Patient Education  61 results see all →